{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+for+allopurinol", "query": { "intervention": "Placebo for allopurinol" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 35, "total_pages": 4, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+for+allopurinol&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-29T20:30:02.333Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00855920", "title": "Study Utilizing Rilonacept in Gout Exacerbations", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Acute Gout Flare" ], "interventions": [ { "name": "Rilonacept", "type": "DRUG" }, { "name": "Indomethacin", "type": "DRUG" }, { "name": "Placebo (for Indomethacin)", "type": "OTHER" }, { "name": "Placebo (for Rilonacept)", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Regeneron Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 225, "start_date": "2009-03", "completion_date": "2010-02", "has_results": true, "last_update_posted_date": "2017-04-28", "last_synced_at": "2026-09-29T20:30:02.333Z", "location_count": 44, "location_summary": "Birmingham, Alabama • Huntsville, Alabama • Mesa, Arizona + 40 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Huntsville", "state": "Alabama" }, { "city": "Mesa", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Sierra Vista", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT00855920" }, { "nct_id": "NCT01129648", "title": "Study to Evaluate sUA-Lowering Activity, Safety & PK Interaction of Oral BCX4208 & Allopurinol Admin. in Subjects w/Gout", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Gout" ], "interventions": [ { "name": "Placebo", "type": "DRUG" }, { "name": "Allopurinol", "type": "DRUG" }, { "name": "BCX4208", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "BioCryst Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "69 Years", "sex": "ALL", "summary": "18 Years to 69 Years" }, "enrollment_count": 87, "start_date": "2010-05", "completion_date": "2010-11", "has_results": false, "last_update_posted_date": "2012-01-23", "last_synced_at": "2026-09-29T20:30:02.333Z", "location_count": 18, "location_summary": "Scottsdale, Arizona • Irvine, California • South Miami, Florida + 15 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Irvine", "state": "California" }, { "city": "South Miami", "state": "Florida" }, { "city": "Honolulu", "state": "Hawaii" }, { "city": "Boise", "state": "Idaho" } ], "official_url": "https://clinicaltrials.gov/study/NCT01129648" }, { "nct_id": "NCT03990363", "title": "A Study of Verinurad and Allopurinol in Patients With Chronic Kidney Disease and Hyperuricaemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Chronic Kidney Disease" ], "interventions": [ { "name": "Verinurad", "type": "DRUG" }, { "name": "Allopurinol", "type": "DRUG" }, { "name": "Placebo for Verinurad", "type": "DRUG" }, { "name": "Placebo for Allopurinol", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "130 Years", "sex": "ALL", "summary": "18 Years to 130 Years" }, "enrollment_count": 861, "start_date": "2019-07-23", "completion_date": "2021-11-22", "has_results": true, "last_update_posted_date": "2023-03-02", "last_synced_at": "2026-09-29T20:30:02.333Z", "location_count": 54, "location_summary": "Huntsville, Alabama • Bakersfield, California • Canyon Country, California + 45 more", "locations": [ { "city": "Huntsville", "state": "Alabama" }, { "city": "Bakersfield", "state": "California" }, { "city": "Canyon Country", "state": "California" }, { "city": "Laguna Hills", "state": "California" }, { "city": "Long Beach", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03990363" }, { "nct_id": "NCT01265264", "title": "Study to Evaluate sUA Lowering Activity, Safety and Efficacy of Oral Ulodesine Added to Allopurinol", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Gout", "Hyperuricemia", "Arthritis", "Joint Disease" ], "interventions": [ { "name": "ulodesine", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "BioCryst Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "69 Years", "sex": "ALL", "summary": "18 Years to 69 Years" }, "enrollment_count": 279, "start_date": "2010-12", "completion_date": "2013-02", "has_results": false, "last_update_posted_date": "2013-11-20", "last_synced_at": "2026-09-29T20:30:02.333Z", "location_count": 54, "location_summary": "Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 51 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT01265264" }, { "nct_id": "NCT00610363", "title": "Study of the Safety and Effectiveness of Rilonacept for the Prevention of Gout Flares", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Gout" ], "interventions": [ { "name": "Rilonacept", "type": "BIOLOGICAL" }, { "name": "Placebo (for Rilonacept)", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "Regeneron Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 83, "start_date": "2007-11", "completion_date": "2008-10", "has_results": true, "last_update_posted_date": "2017-05-02", "last_synced_at": "2026-09-29T20:30:02.333Z", "location_count": 34, "location_summary": "San Diego, California • Santa Maria, California • Whittier, California + 30 more", "locations": [ { "city": "San Diego", "state": "California" }, { "city": "Santa Maria", "state": "California" }, { "city": "Whittier", "state": "California" }, { "city": "Colorado Srings", "state": "Colorado" }, { "city": "DeLand", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00610363" }, { "nct_id": "NCT03226899", "title": "A Phase 4 Safety and Efficacy Study to Evaluate Lesinurad 200 mg in Participants With Gout and Renal Impairment", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Gout", "Chronic Kidney Disease (CKD)" ], "interventions": [ { "name": "Lesinurad", "type": "DRUG" }, { "name": "XOI", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "colchicine", "type": "DRUG" }, { "name": "corticosteroids", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Ironwood Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "18 Years to 85 Years" }, "enrollment_count": 242, "start_date": "2017-07-19", "completion_date": "2019-02-25", "has_results": true, "last_update_posted_date": "2021-11-04", "last_synced_at": "2026-09-29T20:30:02.333Z", "location_count": 70, "location_summary": "Birmingham, Alabama • Tucson, Arizona • Covina, California + 59 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Covina", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "Sacramento", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03226899" }, { "nct_id": "NCT01407874", "title": "A Randomized, Double-Blind, Dose-Response Study of the Safety and Uric Acid Effects of Oral Ulodesine Added to Allopurinol in Subjects With Gout and Concomitant Moderate Renal Insufficiency", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Gout", "Hyperuricemia", "Arthritis", "Joint Disease", "Renal Insufficiency" ], "interventions": [ { "name": "Placebo", "type": "DRUG" }, { "name": "Ulodesine (BCX4208) 5 mg", "type": "DRUG" }, { "name": "Ulodesine (BCX4208) 10 mg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "BioCryst Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "69 Years", "sex": "ALL", "summary": "18 Years to 69 Years" }, "enrollment_count": 20, "start_date": "2011-09", "completion_date": "2012-07", "has_results": false, "last_update_posted_date": "2013-11-20", "last_synced_at": "2026-09-29T20:30:02.333Z", "location_count": 10, "location_summary": "Mobile, Alabama • Peoria, Arizona • Irvine, California + 7 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Peoria", "state": "Arizona" }, { "city": "Irvine", "state": "California" }, { "city": "Oldsmar", "state": "Florida" }, { "city": "Honolulu", "state": "Hawaii" } ], "official_url": "https://clinicaltrials.gov/study/NCT01407874" }, { "nct_id": "NCT02038179", "title": "Center of Research Translation (CORT) Project 2", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Pre-hypertension", "JNC 7 Stage I Hypertension" ], "interventions": [ { "name": "Allopurinol", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Alabama at Birmingham", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "40 Years", "sex": "ALL", "summary": "18 Years to 40 Years" }, "enrollment_count": 99, "start_date": "2014-07", "completion_date": "2018-08", "has_results": true, "last_update_posted_date": "2021-01-11", "last_synced_at": "2026-09-29T20:30:02.333Z", "location_count": 1, "location_summary": "Birmingham, Alabama", "locations": [ { "city": "Birmingham", "state": "Alabama" } ], "official_url": "https://clinicaltrials.gov/study/NCT02038179" }, { "nct_id": "NCT02017171", "title": "A Multicenter Clinical Trial of Allopurinol to Prevent Kidney Function Loss in Type 1 Diabetes", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Diabetic Nephropathies", "Coronary Artery Disease" ], "interventions": [ { "name": "Allopurinol", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Alessandro Doria", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 530, "start_date": "2014-02", "completion_date": "2019-08-31", "has_results": true, "last_update_posted_date": "2020-12-04", "last_synced_at": "2026-09-29T20:30:02.333Z", "location_count": 23, "location_summary": "Aurora, Colorado • Denver, Colorado • Atlanta, Georgia + 15 more", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "Denver", "state": "Colorado" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT02017171" }, { "nct_id": "NCT05818085", "title": "Phase 2b/3 Study to Assess ABP-671 a Novel URAT1 Inhibitor in Participants With Gout", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Gout" ], "interventions": [ { "name": "ABP-671", "type": "DRUG" }, { "name": "Allopurinol", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Atom Therapeutics Co., Ltd", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "19 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "19 Years to 75 Years" }, "enrollment_count": 300, "start_date": "2023-08-11", "completion_date": "2025-03-30", "has_results": false, "last_update_posted_date": "2025-12-22", "last_synced_at": "2026-09-29T20:30:02.333Z", "location_count": 35, "location_summary": "Tempe, Arizona • Tuscon, Arizona • Anaheim, California + 27 more", "locations": [ { "city": "Tempe", "state": "Arizona" }, { "city": "Tuscon", "state": "Arizona" }, { "city": "Anaheim", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "Brooksville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05818085" } ] }